文献速递炎症性肠病

克罗恩病狭窄药物治疗的长期结果

Long-Term Results of Drug Treatment for Crohn's Disease Strictures.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-09-17

STRIDENT试验长期随访显示,症状性克罗恩病狭窄患者接受阿达木单抗联合硫嘌呤强化治疗或阿达木单抗单药治疗12个月后,临床应答者在4年以上随访中手术切除率低于无应答者(20% vs 52%,P < .001),狭窄MRI风险评分可预测无手术生存(OR 2.34,95%CI 1.32-4.16,P = .004)。

要点

  • 临床应答者手术切除率显著低于无应答者(20% vs 52%)。
  • 狭窄MRI风险评分可预测无手术生存(OR 2.34)。
  • 多数患者阿达木单抗临床应答可持续4年以上。

核心结论

  • 阿达木单抗治疗症状性克罗恩病狭窄的临床应答在多数患者中可持续4年以上,药物治疗是可行的初始治疗选择。

研究设计与样本

  • STRIDENT随机对照试验长期随访,77例症状性克罗恩病狭窄患者按2:1随机接受高剂量阿达木单抗诱导后40mg每两周联合硫嘌呤(强化组)或标准剂量阿达木单抗单药(标准组),12个月评估临床应答,至少4年随访访谈。

主要发现

  • 12个月研究期间64/77(83%)完成至少12个月治疗,13例(17%)退出(8例手术,5例其他原因)。
  • 12个月研究完成后,12/77(16%)需内镜下扩张,22/77(29%)需手术。
  • 临床应答者手术切除率低于无应答者(20% vs 52%,P < .001)。
  • 狭窄MRI风险评分预测无手术生存(OR 2.34,95%CI 1.32-4.16,P = .004)。

关键数值与推荐

  • 狭窄MRI风险评分:狭窄前扩张≥30mm、狭窄长度>50mm、肠壁厚度≥10mm各计1分。
  • 临床应答定义为14天梗阻症状评分下降。

临床怎么用

  • 对症状性克罗恩病狭窄患者,可考虑阿达木单抗联合硫嘌呤或阿达木单抗单药作为初始药物治疗。
  • 基线狭窄MRI风险评分可用于预测无手术生存,辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recent controlled data from the STRIDENT study suggest that, in the short-term, drug treatment effectively relieves symptoms and improves bowel wall morphology. Here, we present the long-term results of this clinical trial, identifying predictors of treatment outcomes. METHODS: Patients with symptomatic Crohn's disease strictures were randomized 2:1 to high-dose adalimumab induction followed by 40 mg fortnightly plus thiopurine, with dose increase at 4 and/or 8 months if evidence of persisting inflammation, or standard dose adalimumab monotherapy. Baseline stricture magnetic resonance imaging risk score was assessed: prestenotic dilation ≥30 mm, stricture length >50 mm, and bowel wall thickness ≥10 mm (each factor assigned a score of 1). Patients were assessed at 12 months for clinical response (reduction in the 14-day obstructive symptom score). Follow-up interviews were performed at a minimum of 4 years. RESULTS: In the initial 12-month study, 52 patients were randomized to the intensive and 25 to the standard treatment arm, with 64 of 77 (83%) completing at least 12 months of therapy, whereas 13 patients (17%) withdrew: 8 for surgical treatment and 5 for other reasons. Following study completion at 12 months, 12 of 77 patients (16%) required endoscopic dilation, and 22 of 77 patients (29%) required surgery. Clinical responders had a lower rate of surgical resection compared with nonresponders (20% vs 52%; P < .001). The stricture magnetic resonance imaging risk score predicted surgery-free survival (odds ratio, 2.34; 95% confidence interval, 1.32-4.16; P = .004). CONCLUSIONS: The clinical response to adalimumab is durable in a majority of patients beyond 4 years of therapy. In patients with symptomatic Crohn's disease strictures, drug treatment is a viable initial treatment. Stricture Definition and Treatment (STRIDENT) Drug Therapy Study: Clinicaltrials.gov, Number: NCT03220841.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lovett GC, Schulberg JD, Hamilton AL, et al. Long-Term Results of Drug Treatment for Crohn's Disease Strictures. Clin Gastroenterol Hepatol. 2025. PMID: 40972879. doi:10.1016/j.cgh.2025.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。